A new angle on immunotherapy
Cancer cells injured by chemotherapy can be harnessed to unleash the immune system against tumors in mice.

Immunotherapy offers the promise of stimulating the body’s immune system to destroy tumor cells, but it only works for a handful of cancers. MIT researchers have now discovered a novel technique that they hope could enable it to target more types.
The surprising key to the approach is using chemotherapy to injure cancer cells without killing them. Led by professors Michael Yaffe and Darrell Irvine, the researchers remove tumor cells from the body, treat them with existing drugs, and then place them back in the tumor. When delivered along with drugs that activate the immune system’s T cells, these injured cancer cells appear to act as a distress signal that spurs the T cells into action against the tumors. Chemotherapy drugs that cause DNA damage are especially well suited for this type of treatment.
In 40% of mice with melanoma and breast tumors, the treatment completely eliminated the tumors. And when the researchers injected cancer cells into these same mice several months later, their T cells recognized them and destroyed them before they could form new tumors.
“When you create cells that have DNA damage but are not killed, under certain conditions those live, injured cells can send a signal that awakens the immune system,” says Yaffe. He hopes to test the approach in patients whose cancers have not responded to other immunotherapy.
Keep Reading
Most Popular

Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.